CliffBio
biologic

Tremfya

guselkumab

Loss of exclusivitySeptember 2036projected — 12-year biologic exclusivity estimate
CompanyJanssen Biotech →View the full company profile on CliffBio

Drug detail

Brand nameTremfya
Active ingredientguselkumab
Strength200MG/20ML (10MG/ML)
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalSeptember 2024
Marketing statusRx

More from Janssen Biotech

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Tremfya patent cliff — loss of exclusivity September 2036 | CliffBio